Paper19085949
Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases.
Brinker AD and 6 others. Hepatology, 2009. Cited by 76 papers, by iCite.
Cite this record
ConductScience Library. Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. Papers, record 19085949. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19085949
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Chemical and Drug Induced Liver Injury | Major topic |
| Ketolides | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Ascites | |
| Fatal Outcome | |
| Female | |
| Humans | |
| Jaundice | |
| Liver Failure | |
| Male | |
| Middle Aged | |
| Pleural Effusion |
Source PubMed
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 76 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38418669 | Natural Products for the Management of Asthma and COPD. | Handb Exp Pharmacol | 2025 | https://conductscience.org/library/papers/38418669 | PubMed |
| 36808265 | Novel read through agent: ZKN-0013 demonstrates efficacy in APCmin model of familial adenomatous polyposis. | J Mol Med (Berl) | 2023 | https://conductscience.org/library/papers/36808265 | PubMed |
| 35188588 | Impact of novel microbial secondary metabolites on the pharma industry. | Appl Microbiol Biotechnol | 2022 | https://conductscience.org/library/papers/35188588 | PubMed |
| 32647996 | An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids. | Drug Saf | 2020 | https://conductscience.org/library/papers/32647996 | PubMed |
| 32019171 | Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms. | Microorganisms | 2020 | https://conductscience.org/library/papers/32019171 | PubMed |
| 30992910 | Causality assessment: Which is best-expert opinion or RUCAM? | Clin Liver Dis (Hoboken) | 2014 | https://conductscience.org/library/papers/30992910 | PubMed |
| 30734107 | Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems Toxicology Modeling. | Pharm Res | 2019 | https://conductscience.org/library/papers/30734107 | PubMed |
| 28971877 | In Vitro Activity of the Novel Lactone Ketolide Nafithromycin (WCK 4873) against Contemporary Clinical Bacteria from a Global Surveillance Program. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/28971877 | PubMed |
| 28443154 | Drug-induced liver injury: Do we know everything? | World J Hepatol | 2017 | https://conductscience.org/library/papers/28443154 | PubMed |
| 28314920 | [New antibiotics - standstill or progress]. | Med Klin Intensivmed Notfmed | 2017 | https://conductscience.org/library/papers/28314920 | PubMed |
| 27909995 | Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. | Drugs | 2016 | https://conductscience.org/library/papers/27909995 | PubMed |
| 27353268 | Macrolones Are a Novel Class of Macrolide Antibiotics Active against Key Resistant Respiratory Pathogens In Vitro and In Vivo. | Antimicrob Agents Chemother | 2016 | https://conductscience.org/library/papers/27353268 | PubMed |
| 27000559 | Targeting Antibiotic Resistance. | Angew Chem Int Ed Engl | 2016 | https://conductscience.org/library/papers/27000559 | PubMed |
| 26633044 | Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. | Expert Rev Gastroenterol Hepatol | 2016 | https://conductscience.org/library/papers/26633044 | PubMed |
| 26524373 | [Advancement in chronic drug-induced liver injury]. | Zhonghua Gan Zang Bing Za Zhi | 2015 | https://conductscience.org/library/papers/26524373 | PubMed |
| 26167249 | Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk. | World J Hepatol | 2015 | https://conductscience.org/library/papers/26167249 | PubMed |
| 25232453 | Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. | World J Hepatol | 2014 | https://conductscience.org/library/papers/25232453 | PubMed |
| 25086050 | "First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs. | Am J Epidemiol | 2014 | https://conductscience.org/library/papers/25086050 | PubMed |
| 24379197 | In vitro activity of solithromycin against erythromycin-resistant Streptococcus agalactiae. | Antimicrob Agents Chemother | 2014 | https://conductscience.org/library/papers/24379197 | PubMed |
| 24178291 | Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database. | Drug Saf | 2013 | https://conductscience.org/library/papers/24178291 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19085949
GET https://conductscience.org/api/papers/v1/19085949/cited_by?page=2